In patients with chronic lymphocytic leukaemia (CLL), there are two types of medicines that target the B cell receptor (BCR): Bruton’s tyrosine kinase (BTK) inhibitors (BTKis) and phosphoinositide 3-kinase inhibitors (PI3Kis)57,.58 Here, BTK is linked to B-cell chronic lymphocytic leukemia.